



(51) International Patent Classification:

C07D 493/10 (2006.01) **A61K 31/357** (2006.01)
C07H 15/18 (2006.01) **A61P 3/10** (2006.01)

(21) International Application Number:

PCT/IB2009/053626

(22) International Filing Date:

17 August 2009 (17.08.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/092,470 28 August 2008 (28.08.2008) US
61/227,212 21 July 2009 (21.07.2009) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MASCITTI, Vincent** [FR/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).
COLLMAN, Benjamin, Micah [US/US]; Pfizer Global

Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **BENSON, Gregg, C.**; c/o Pfizer Inc. Eastern Point Road MS9114, Groton, Connecticut 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,

[Continued on next page]

(54) Title: DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES

FIG. 9





FIG. 1

(57) Abstract: Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). The compounds disclosed herein are useful for the prevention and treatment of obesity and its associated co-morbidities, in particular type II (type 2) diabetes.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))